Skip to main content

Table 4 The change of the volume, expenditures, and DDDc of each “4 + 7” List antihypertensive drug in the pre- and post-“4 + 7” periods

From: The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis

  Volume (million DDD) Expenditures (million CNY) DDDc (CNY)
  Pre- Post- GR (%) Pre- Post- GR (%) Pre- Post- GR (%)
Amlodipine 11790.55 26305.12 123.10 39505.03 15424.75 -60.95 3.35 0.59 -82.50
Irbesartan 6017.09 9736.77 61.82 15173.01 7709.53 -49.19 2.52 0.79 -68.60
Irbesartan
hydrochlorothiazide
1909.19 3899.69 104.26 6639.64 5545.92 -16.47 3.48 1.42 -59.11
Fosinopril 572.97 657.15 14.69 3081.37 1531.17 -50.31 5.38 2.33 -56.67
Lisinopril 0.00 6.02 - 0.00 2.77 - - 0.46 -
Losartan 3339.10 4749.23 42.23 8872.47 5702.14 -35.73 2.66 1.20 -54.81
Enalapril 900.38 1780.08 97.70 540.23 1523.16 181.95 0.60 0.86 42.61
Total 24529.28 47134.07 92.15 73811.75 37439.44 -49.28 3.01 0.79 -73.60
  1. DDD, Daily Defined Dose; CNY, Chinese Yuan; DDDc, Defined Daily Drug cost; GR, Growth Rate. Pre- refers to March to December 2018; Post- refers to March to December 2019